Pulmatrix and Eos SENOLYTIX have announced a merger that will create a new entity focused on advancing gerotherapeutics, a field targeting the biology of aging rather than its symptoms. Operating under the name Eos and trading as EOSX, the company aims to develop its lead candidate, PTC-2105, for conditions like sarcopenia. This merger, supported by $19 million in financing, signals a significant shift in biopharma’s approach to aging, treating it as a manageable driver of disease.

The combined company’s strategy centers on MitoXcel, a platform designed to modulate mitochondrial function and eliminate senescent cells, which are implicated in metabolic decline and frailty. By addressing these upstream biological factors, Eos hopes to improve not just weight loss outcomes but also overall health, emphasizing the importance of lean mass preservation alongside fat loss. This approach positions Eos as a complementary player in the evolving landscape of obesity and aging therapeutics.

As the field of longevity science gains traction within mainstream medicine, the implications of this merger extend beyond a single product. The focus is shifting from merely treating symptoms to addressing the underlying mechanisms of aging, potentially transforming how we approach age-related diseases. The success of Eos’s platform could pave the way for broader applications in age-related conditions, marking a pivotal moment in the professionalization of longevity research.

Source: longevity.technology